Refine
Year of publication
Document Type
- Article (27)
- Working Paper (3)
- Preprint (2)
Language
- English (32)
Has Fulltext
- yes (32)
Is part of the Bibliography
- no (32)
Keywords
- AML (3)
- Acute myeloid leukemia (3)
- regulatory arbitrage (3)
- Capital Markets Union (2)
- Central Counterparties (2)
- Chemotherapy (2)
- EMIR (2)
- European Supervisory Architecture (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Induction chemotherapy (2)
- Survival (2)
- supervisory arbitrage (2)
- ALK-rearranged NSCLC (1)
- Allograft bone block (1)
- Antibiotic steward-ship (1)
- Antibiotics (1)
- Autogenous bone block (1)
- BCOR (1)
- BCORL1 (1)
- BFIS (1)
- Bone marrow (1)
- Bone marrow aspiration (1)
- Brexit (1)
- CBC (1)
- CDI (1)
- CVID (1)
- Cancer chemotherapy (1)
- Capnography (1)
- Clinical Trials and Observations (1)
- Cytogenetics (1)
- Death rates (1)
- Deletion mutation (1)
- ESBL (1)
- Endoscopy (1)
- Enterobacteriaceae (1)
- European Society for Immunodeficiencies (ESID) (1)
- Fevers (1)
- Fluid overload (1)
- German PID-NET registry (1)
- Heavy Ion Experiments (1)
- Hepatocellular carcinoma (1)
- Hospitals (1)
- Hypoxia (1)
- IgG substitution therapy (1)
- IgG4-related disease (1)
- Indeterminate biliary stricture (1)
- Infection (1)
- Integrated Pulmonary Index (1)
- Intensive care treatment (1)
- Karyotypes (1)
- Liver cancer (1)
- Long term result (1)
- Methicillin-resistant Staphylococcus aureus (1)
- Monitoring (1)
- Multidrug-resistant organisms (1)
- Myeloid Neoplasia (1)
- Neutropenia (1)
- PID prevalence (1)
- PKD (1)
- PKD/IC (1)
- PRRT2 (1)
- Percutaneous endoscopic gastrostomy (1)
- Peripheral blood smears (1)
- Pink esthetic score (1)
- Relapse surveillance (1)
- TP53 mutation status (1)
- VRE (1)
- Vacuoles (1)
- acute myeloid leukemia (1)
- bile duct stenosis (1)
- bleeding (1)
- endoscopic retrograde cholangiopancreatography (1)
- endoscopy (1)
- eosinophilic cholangitis (1)
- familial infantile epilepsy (1)
- financial innovations (1)
- hemiplegic migraine (1)
- induction chemotherapy (1)
- intracranial hemorrhage (1)
- leasing (1)
- loss-of-function (1)
- phenotypic spectrum (1)
- platelet substitution (1)
- primary immunodeficiency (PID) (1)
- primary sclerosing cholangitis (1)
- registry for primary immunodeficiency (1)
- regulation (1)
- risk stratification (1)
- sequential ALK-inhibitor therapy (1)
- survival (1)
Institute
The optimal follow-up care for relapse detection in acute myeloid leukemia (AML) patients in first remission after consolidation therapy with intensive chemotherapy is not established. In this retrospective study, we evaluate the diagnostic value of an intensive relapse surveillance strategy by regular bone marrow aspirations (BMA) in these patients. We identified 86 patients with newly diagnosed non-promyelocytic AML who had reached complete remission (CR) after intensive induction and consolidation chemotherapy between 2007 and 2019. Annual relapse rates were 40%, 17%, and 2% in years 1–3, respectively. Patients in CR were surveilled by BMA scheduled every 3 months for 2 years, followed by BMA every 6 months. This surveillance regimen detected 29 of 55 relapses (53%), 11 of which were molecular relapses (20%). The remaining 26 of 55 relapses (47%) were diagnosed by non-surveillance BMA prompted by specific suspicion of relapse. Most patients showed concurrent morphological abnormalities in peripheral blood (PB) at time of relapse. Seven percent of all morphological relapses occurred without simultaneous PB abnormalities and would have been delayed without surveillance BMA. Intensified monthly PB assessment paired with BMA every 3 months during the first 2 years may be a highly sensitive relapse surveillance strategy.
Pathogenic variants in PRRT2, encoding the proline-rich transmembrane protein 2, have been associated with an evolving spectrum of paroxysmal neurologic disorders. Based on a cohort of children with PRRT2-related infantile epilepsy, this study aimed at delineating the broad clinical spectrum of PRRT2-associated phenotypes in these children and their relatives. Only a few recent larger cohort studies are on record and findings from single reports were not confirmed so far. We collected detailed genetic and phenotypic data of 40 previously unreported patients from 36 families. All patients had benign infantile epilepsy and harbored pathogenic variants in PRRT2 (core cohort). Clinical data of 62 family members were included, comprising a cohort of 102 individuals (extended cohort) with PRRT2-associated neurological disease. Additional phenotypes in the cohort of patients with benign sporadic and familial infantile epilepsy consist of movement disorders with paroxysmal kinesigenic dyskinesia in six patients, infantile-onset movement disorders in 2 of 40 individuals, and episodic ataxia after mild head trauma in one girl with bi-allelic variants in PRRT2. The same girl displayed a focal cortical dysplasia upon brain imaging. Familial hemiplegic migraine and migraine with aura were reported in nine families. A single individual developed epilepsy with continuous spikes and waves during sleep. In addition to known variants, we report the novel variant c.843G>T, p.(Trp281Cys) that co-segregated with benign infantile epilepsy and migraine in one family. Our study highlights the variability of clinical presentations of patients harboring pathogenic PRRT2 variants and expands the associated phenotypic spectrum.